AiRuiKa (camrelizumab)

Furthermore, through computer-simulated clinical trials, we find that reducing the dose of apatinib in combination therapy to 125 mg can still achieve therapeutic effects comparable to the original dose. These findings provide valuable insights for future drug development and clinical trial design.

Neoadjuvant MCT combined with camrelizumab led to an increased pCR rate (54.5 vs. 16.7%) in ESCC patients compared to MCT alone. This combination therapy may offer a promising approach for enhancing cancer treatment outcomes.

P3, N=231, Active, not recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Trial completion date: Mar 2026 --> Mar 2028

P2, N=72, Recruiting, Shandong Cancer Hospital and Institute | N=20 --> 72

He received 7 months of crizotinib as first-line therapy, after that, the lung and brain lesions enlarged. The combination of brain radiotherapy and camrelizumab demonstrated efficacy in a lung adenocarcinoma patient with BM and METex14. These findings suggest that immunotherapy may represent a potential treatment approach for high PD-L1 expression of METex14 NSCLC patients, warranting further investigation in larger cohorts.

Adjuvant immunotherapies for lung cancer deliver meaningful clinical benefits, but their economic value and affordability are highly context-specific. While several strategies are cost-effective at the individual patient level, health system affordability is strongly influenced by the pace and scale of adoption. Scenario-based budget impact analyses demonstrate that accelerated uptake can impose substantial short-term fiscal pressure, whereas phased or restricted implementation markedly improves affordability without altering cost-effectiveness conclusions. These findings underscore the importance of integrating cost-effectiveness evidence with explicit consideration of budget impact, adoption strategies, and managed entry mechanisms to support sustainable and equitable scale-up of adjuvant immunotherapies in routine clinical practice.

P2, N=30, Active, not recruiting, First Affiliated Hospital of Zhejiang University | Recruiting --> Active, not recruiting | Trial completion date: Sep 2025 --> Dec 2026

P2, N=50, Not yet recruiting, National Medical Research Radiological Centre of the Ministry of Health of Russia

P2, N=19, Not yet recruiting, Beijing Friendship Hospital

P2, N=68, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine

The addition of CIK cell therapy to anti-PD-1 antibody showed signals of potential benefit in refractory ccRCC with a tolerable safety profile. This pilot study suggests the combination approach appears feasible and warrants investigation in larger trials in pretreated ccRCC patients.Registry: ClinicalTrials.gov, TRN: NCT03987698, Registration date: 17 June 2019.

P2, N=94, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting